Charles James Franson Jr., D.O. General Practice Medicare: Accepting Medicare Assignments Practice Location: 345 W Madison St, Starke, FL 32091 Phone: 904-964-5455 |
Mr. Elio Madan, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 132 E Madison St, Starke, FL 32091 Phone: 904-964-6500 Fax: 904-964-9170 |
Dr. Jorge Gilete Sosa, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 1801 N Temple Ave, Starke, FL 32091 Phone: 904-964-7732 Fax: 904-964-3024 |
Jean Maurice Dure, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1801 N Temple Ave, Starke, FL 32091 Phone: 904-964-7732 Fax: 904-964-3829 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
A study co-directed by the Universidad Complutense de Madrid and La Paz hospital in Madrid identifies a protein of high expression in cells located at the tumour boundary that could play an essential role in the evolution of tumours and their invasive potential.
Cancer immunotherapy - empowering a patient's own immune system to clear away tumors on its own - holds great promise for some patients. But for other patients, immunotherapy just doesn't work.
Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.
› Verified 6 days ago